Atopic dermatitis (eczema) trials in China

In China 57 Also abroad 251

57 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Where
Beijing, Changsha, Hangzhou, Nanchang, Shanghai, Shenzhen
Age
2 years to 11 years
People
450 worldwide
Run by
Pfizer
See details and how to joinNCT06807281 · EU 2023-509124-18-00
Phase 2Taking people
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Where
Beijing, Fuzhou, Guangzhou, Shanghai
Age
18 years to 64 years
People
165 worldwide
Run by
Pfizer
See details and how to joinNCT07216027 · EU 2025-522965-31-00
Phase 1Taking people
A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis
Where
Beijing, Fuzhou, Hangzhou, Jinan, Nanchang, Shanghai
Age
18 years to 65 years
People
84 worldwide
Run by
Zai Lab (Shanghai) Co., Ltd.
See details and how to joinNCT07235384
No phaseTaking people
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Where
Beijing, Changsha, Chengdu, Chongqing, Hangzhou, Ningbo, Shanghai, Shenzhen, Xi’an
Age
12 years and over
People
1,000 worldwide
Run by
Sanofi
See details and how to joinNCT07290803
Phase 2Taking people
Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Where
Hangzhou
Age
18 years to 75 years
People
160
Run by
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
See details and how to joinNCT07895615
Phase 3Taking people
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis
Where
Hangzhou
Age
12 years and over
People
240
Run by
Galderma R&D
See details and how to joinNCT07762833
Phase 3Taking people
A Phase III Study of GS101 Injection to Dupixent®
Where
Shenyang
Age
18 years to 75 years
People
572
Run by
Jiangsu Genscend Biopharmaceutical Co., Ltd
See details and how to joinNCT07386743
Phase 3Taking people
A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis
Where
Guangzhou
Age
18 years to 75 years
People
520
Run by
Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07754786
Phase 3Taking people
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
Where
Beijing, Changsha, Guangzhou, Hangzhou
Age
2 years to 11 years
People
246
Run by
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
See details and how to joinNCT07767253
Phase 1Taking people
Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis
Where
Shanghai
Age
18 months to 65 years
People
84
Run by
QuantX Biosciences, Inc.
See details and how to joinNCT07800104
Phase 2Taking people
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Where
Beijing, Changchun, Changsha, Guangzhou, Hangzhou, Shanghai, Shantou
Age
18 years to 100 years
People
224 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06947993 · EU 2024-519081-49-00
Phase 3Taking people
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Where
Beijing, Changsha, Hangzhou, Nanchang, Shanghai, Shenzhen
Age
6 years to 11 years
People
150 worldwide
Run by
Pfizer
See details and how to joinNCT06807268 · EU 2023-509121-51-00
Phase 3Taking people
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
Where
Shanghai, Shenyang
Age
12 years to 17 years
People
201
Run by
Guangdong Hengrui Pharmaceutical Co., Ltd
See details and how to joinNCT07309055
Phase 1Not yet taking people in China
A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
Where
Hangzhou
Age
18 years to 70 years
People
68
Run by
Helixon Biotechnology (Suzhou) Co., Ltd
See details and how to joinNCT07801612
Phase 1/2Taking people
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
Where
Beijing
Age
18 years to 75 years
People
24
Run by
Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
See details and how to joinNCT06931990
Phase 3Taking people
Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis
Where
Beijing
Age
18 years to 75 years
People
480
Run by
Shanghai Longwood Biopharmaceuticals Co., Ltd.
See details and how to joinNCT07370909
Phase 2/3Not yet taking people in China
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profiles of TLL-018 in Patients With Moderate-to-Severe Atopic Dermatitis
Where
Beijing
Age
18 years to 75 years
People
390
Run by
Hangzhou Highlightll Pharmaceutical Co., Ltd
See details and how to joinNCT07784816
Phase 1/2Not yet taking people in China
Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
Where
Hangzhou
Age
18 years to 70 years
People
67
Run by
Helixon Biotechnology (Suzhou) Co., Ltd
See details and how to joinNCT07782476
Phase 3Taking people
Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Where
Nanjing
Age
18 years to 75 years
People
480
Run by
Jiangsu vcare pharmaceutical technology co., LTD
See details and how to joinNCT06723080
Phase 1Taking people
A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Where
Beijing, Changsha, Guangzhou, Hefei, Jinan, Nanchang, Shanghai, Wuhu, Wuxi, Zhenjiang
Age
18 years to 65 years
People
99
Run by
Bambusa Therapeutics
See details and how to joinNCT07239947
Phase 1Taking people
A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
Where
Shanghai
Age
18 years to 45 years
People
96
Run by
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
See details and how to joinNCT07693738
Phase 3Taking people
Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
Where
Nanjing
Age
12 years and over
People
360
Run by
Jiangsu vcare pharmaceutical technology co., LTD
See details and how to joinNCT07592585
Phase 2Taking people
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
Where
Hangzhou
Age
18 years and over
People
120
Run by
Jiangsu vcare pharmaceutical technology co., LTD
See details and how to joinNCT07598383
Phase 2Not yet taking people in China
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching
Where
Shanghai
Age
18 years to 70 years
People
44
Run by
RenJi Hospital
See details and how to joinNCT07678645
Phase 1/2Taking people
HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
Where
Hangzhou
Age
18 years to 75 years
People
156
Run by
Hangzhou Highlightll Pharmaceutical Co., Ltd
See details and how to joinNCT07629778